← Back to Screener
Bon Natural Life Limited Class A Ordinary Shares (BON)
Price$1.25
Value ScoreB
Growth ScoreD
Momentum ScoreD
Favorite Metrics
Price vs S&P 500 (26W)-40.36%
Price vs S&P 500 (4W)4.18%
VGM Score40.29
Market Capitalization$10.16M
All Metrics
P/CF (Annual)72.00x
Book Value / Share (Quarterly)$7.08
P/TBV (Annual)0.24x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-14.54%
Cash Flow / Share (Quarterly)$-1.21
Price vs S&P 500 (YTD)-29.54%
Gross Margin (TTM)20.77%
Net Profit Margin (TTM)-10.68%
EPS (TTM)$0.09
10-Day Avg Trading Volume0.02M
EPS Excl Extra (TTM)$0.09
Revenue Growth (5Y)0.49%
EPS (Annual)$-0.72
ROI (Annual)-2.86%
Gross Margin (Annual)20.77%
Net Profit Margin (5Y Avg)9.08%
Cash / Share (Quarterly)$0.46
Revenue Growth QoQ (YoY)-21.52%
ROA (Last FY)-2.34%
Revenue Growth TTM (YoY)-21.70%
EBITD / Share (TTM)$-0.19
ROE (5Y Avg)9.83%
Operating Margin (TTM)-8.69%
Cash Flow / Share (Annual)$-1.21
P/B Ratio0.18x
P/B Ratio (Quarterly)0.21x
Net Income / Employee (Annual)$-20,800
EV / Revenue (TTM)0.99x
Net Interest Coverage (TTM)-3.68x
ROA (TTM)-2.54%
EV / EBITDA (TTM)5.97x
EPS Incl Extra (Annual)$-0.72
Current Ratio (Annual)1.74x
Quick Ratio (Quarterly)1.28x
3-Month Avg Trading Volume0.05M
52-Week Price Return-30.17%
EV / Free Cash Flow (Annual)5.38x
Revenue / Employee (TTM)$194,500
Tangible BV / Share (Quarterly)$6.29
P/S Ratio (Annual)0.54x
Asset Turnover (Annual)0.22x
52-Week High$3.40
Operating Margin (5Y Avg)12.45%
EPS Excl Extra (Annual)$-0.72
CapEx CAGR (5Y)18.20%
26-Week Price Return-32.43%
Quick Ratio (Annual)1.28x
13-Week Price Return-14.38%
Total Debt / Equity (Annual)0.21x
Current Ratio (Quarterly)1.74x
Enterprise Value$18.57M
Revenue / Share Growth (5Y)-21.53%
Asset Turnover (TTM)0.24x
Revenue / Employee (Annual)$194,500
Inventory Turnover (Annual)6.07x
Pretax Margin (Annual)-9.16%
Cash / Share (Annual)$0.46
3-Month Return Std Dev37.98%
Gross Margin (5Y Avg)27.99%
Net Income / Employee (TTM)$-20,800
ROE (Last FY)-3.47%
Net Interest Coverage (Annual)-3.68x
EPS Basic Excl Extra (Annual)$-0.72
P/FCF (TTM)28.78x
Receivables Turnover (TTM)1.64x
EV / Free Cash Flow (TTM)1.87x
Total Debt / Equity (Quarterly)0.21x
EPS Incl Extra (TTM)$0.09
Receivables Turnover (Annual)1.64x
ROI (TTM)-3.02%
P/S Ratio (TTM)0.54x
Pretax Margin (5Y Avg)11.81%
Revenue / Share (Annual)$6.78
Tangible BV / Share (Annual)$6.29
Forward P/E2.18x
Price vs S&P 500 (52W)-54.53%
EPS Growth TTM (YoY)-96.73%
Year-to-Date Return-21.38%
5-Day Price Return0.00%
EPS Normalized (Annual)$-0.72
ROA (5Y Avg)7.50%
Net Profit Margin (Annual)-10.68%
Month-to-Date Return-1.30%
Cash Flow / Share (TTM)$0.71
EBITD / Share (Annual)$-0.19
Operating Margin (Annual)-8.69%
LT Debt / Equity (Annual)0.01x
P/CF (TTM)72.00x
ROI (5Y Avg)8.74%
LT Debt / Equity (Quarterly)0.01x
EPS Basic Excl Extra (TTM)$0.09
P/TBV (Quarterly)0.24x
P/B Ratio (Annual)0.21x
Inventory Turnover (TTM)6.07x
Pretax Margin (TTM)-9.16%
Book Value / Share (Annual)$7.08
Price vs S&P 500 (13W)-22.64%
Beta-0.27x
P/FCF (Annual)339.83x
Revenue / Share (TTM)$3.59
ROE (TTM)-3.59%
52-Week Low$1.13
vGradeB
gGradeD
mGradeD
vgmGradeC
Show chart for
Industry Peers — Pharmaceutical Preparations(17)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BONBon Natural Life Limited Class A Ordinary Shares | B | D | D | $1.25 |
| DFTXDefinium Therapeutics, Inc. Common Shares | — | — | A | $23.55 |
| CRONCronos Group Inc. Common Share | C | B | B | $2.74 |
| TLRYTilray Brands, Inc. Common Stock | B | B | D | $4.94 |
| CGCCanopy Growth Corporation Common Shares | C | D | C | $1.03 |
| USNAUSANA Health Sciences Inc | B | D | C | $18.03 |
| NAGENiagen Bioscience, Inc. Common Stock | C | B | D | $3.45 |
| SNDLSundial Growers Inc. Common Shares | A | C | C | $1.42 |
| ACBAurora Cannabis Inc. Common Shares | B | C | C | $3.38 |
| MDWDMediWound Ltd. | D | F | D | $14.18 |
| FTLFFitLife Brands, Inc. Common Stock | B | C | D | $9.87 |
About
Bon Natural Life Ltd manufactures natural personal care and health ingredients, primarily plant-extracted fragrance compounds for cosmetic applications, along with natural health supplements and bioactive food ingredients. The company has developed proprietary technology platforms for extraction, safety enhancement, and functional compounding of natural products. Revenue is primarily derived from fragrance compound sales to perfume and cosmetic manufacturers, with additional revenue from supplement and food ingredient customers.